University of Oxford | Oxford Vaccine Centre - Oxford Vaccine Group

Research site

(Unclaimed)

Location

Oxford Vaccine Centre, CCVTM Churchill Hospital, Oxford, Oxfordshire, England

Site insights

Top conditions

Top treatments

Ruxolitinib

PF-04995274

Upadacitinib

Prucalopride

Citalopram

Apitegromab

Octreotide

REGN4018

Lamotrigine

IMC-F106C

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 100 total trials

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) a...

Enrolling

Myeloproliferative Neoplasms

Drug: INCA033989

Drug: Ruxolitinib

Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam (SAPPHIRE)

This Phase 3 trial (Study SRK-015-003) is being conducted in patients ≥2 years old at Screening, who were previously diagnosed with later-onset spina...

Active, not recruiting

Anti-myostatin

Neuromuscular Manifestations

Drug: Placebo

Drug: Apitegromab

Improving Sleep and Learning in Rehabilitation After Stroke, Part 2 (INSPIRES-2)

This study will explore whether sleep in stroke survivors is improved with digital cognitive behavioural therapy for insomnia (Sleepio), in compariso...

Enrolling

Stroke

Behavioral: Digital Cognitive Behavioural Therapy for Insomnia

Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab-ONYX

The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Ty...

Active, not recruiting

Anti-myostatin

Neuromuscular Manifestations

Drug: Apitegromab

Reward Emotion Learning and Ketamine Study (RELAKS)

Ketamine's efficacy as an antidepressant is now well established yet the mechanisms underlying its antidepressant effect are yet to be fully describe...

Enrolling

Major Depressive Disorder

Treatment Resistant Depression

Other: No intervention (placebo)

Drug: Ketamine Hydrochloride

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-a...

Enrolling

Select Advanced Solid Tumors

Drug: IMC-F106C and monoclonal antibodies and chemotherapy

Drug: IMC-F106C and chemotherapy

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxoliti...

Enrolling

ET (Essential Thrombocythemia)

Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)

Drug: INCB057643

Drug: Ruxolitinib

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

The main purpose of this study is to:* Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or with cemiplimab...

Enrolling

Recurrent Primary Peritoneal Cancer

Recurrent Ovarian Cancer

Drug: REGN4018

Drug: Sarilumab

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms